Financials data is unavailable for this security.
View more
Year on year Fuji Pharma Co Ltd grew revenues 12.84% from 40.89bn to 46.14bn while net income improved 78.87% from 3.44bn to 6.15bn.
Gross margin | 39.28% |
---|---|
Net profit margin | 14.28% |
Operating margin | 11.75% |
Return on assets | 7.36% |
---|---|
Return on equity | 14.90% |
Return on investment | 11.63% |
More ▼
Cash flow in JPYView more
In 2024, Fuji Pharma Co Ltd increased its cash reserves by 97.29%, or 2.26bn. The company earned 4.15bn from its operations for a Cash Flow Margin of 9.00%. In addition the company used 1.66bn on investing activities and also paid 435.00m in financing cash flows.
Cash flow per share | 405.15 |
---|---|
Price/Cash flow per share | 3.33 |
Book value per share | 1,849.15 |
---|---|
Tangible book value per share | 1,415.66 |
More ▼
Balance sheet in JPYView more
Current ratio | 1.21 |
---|---|
Quick ratio | 0.6276 |
Total debt/total equity | 0.6426 |
---|---|
Total debt/total capital | 0.3912 |
More ▼
Growth rates in JPY
SmartText is unavailable
Div yield(5 year avg) | 2.68% |
---|---|
Div growth rate (5 year) | 5.73% |
Payout ratio (TTM) | 15.28% |
EPS growth(5 years) | 4.64 |
---|---|
EPS (TTM) vs TTM 1 year ago | 212.43 |
More ▼